Last updated: 7 May 2024 at 6:36pm EST

William Burnside Net Worth



William Burnside biography

William H. L. Burnside is an Independent Director of the Company. Mr. Burnside is a retired senior vice president and director at The Boston Consulting Group (BCG), where he currently serves as an advisor. Prior to becoming managing partner of BCG's Los Angeles office in 1987, he worked in BCG's London and Chicago offices, servicing clients in telecommunications, media, defense, financial services, and manufacturing. Mr. Burnside is a director at Audubon California.

What is the salary of William Burnside?

As the Independent Director of Abbvie Inc, the total compensation of William Burnside at Abbvie Inc is $333,707. There are 15 executives at Abbvie Inc getting paid more, with Richard Gonzalez having the highest compensation of $21,610,600.



How old is William Burnside?

William Burnside is 67, he's been the Independent Director of Abbvie Inc since 2013. There are 3 older and 28 younger executives at Abbvie Inc. The oldest executive at Abbvie Inc is Edward Liddy, 73, who is the Independent Director.

What's William Burnside's mailing address?

William's mailing address filed with the SEC is North Waukegan Road, North Chicago, Lake County, Illinois, 60044, United States.

Insiders trading at Abbvie Inc

Over the last 12 years, insiders at Abbvie Inc have traded over $324,915,370 worth of Abbvie Inc stock and bought 214,015 units worth $14,446,494 . The most active insiders traders include Richard A Gonzalez, Frederick H Waddell y Glenn F Tilton. On average, Abbvie Inc executives and independent directors trade stock every 22 days with the average trade being worth of $7,529,855. The most recent stock trade was executed by Richard A Gonzalez on 5 August 2024, trading 66,500 units of ABBV stock currently worth $12,403,580.



What does Abbvie Inc do?

AbbVie Inc. is a pharmaceutical company headquartered in North Chicago, Illinois. It is ranked 6th on the list of largest biomedical companies by revenue. Their primary product is Humira (adalimumab) ($21 billion in 2022 revenues, 37% of total), administered via injection. It is approved to treat autoimmune diseases including rheumatoid arthritis, Crohns disease, plaque psoriasis, and ulcerative colitis.



What does Abbvie Inc's logo look like?

Abbvie Inc logo

Abbvie Inc executives and stock owners

Abbvie Inc executives and other stock owners filed with the SEC include: